Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 DSM, Eisai In Master Supply Pact | Contract Pharma
Breaking News

DSM, Eisai In Master Supply Pact

DSM will produce eribulin mesylate for the U.S. market

DSM Pharmaceutical Products has signed a three-year master supply agreement with Eisai Inc., based in Woodcliff Lake, NJ, for the production of sterile products, including eribulin mesylate and other developmental drugs. DSM will supply eribulin mesylate for the U.S. market with commercial production expected to begin in early 2013. DSM will manufacture the product at its finished dosage facility in Greenville, NC. Financial details were not disclosed.
 
Laura Parks, president of DSM Pharmaceuticals, Inc., the finished dosage business of DSM, said, “It has been an honor to work with Eisai through the launch into commercial supply of eribulin mesylate and to continue to support the development of other products.  Combining the expertise of Eisai in developing innovative medicines with DSM’s strength in GMP, and supply chain management will provide critical high quality treatments for patients.”
 
“Eisai appreciates the focus and effort the DSM Pharmaceuticals team in Greenville has provided in support of our commercial and developmental products.  We are particularly pleased to have received FDA approval to manufacture eribulin mesylate at DSM for the commercial U.S. market.  This alternate site of manufacturing strengthens the supply reliability of this important product for our patients,” said Shawn Gallagher, president of partnership management CFU, Eisai Inc.
 

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters